title: [Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney transplantation].
abstract: Malignancies and opportunistic infections are frequently observed after solid-organ transplantation. Their occurrence strongly affects recipient survival. We report the case of a 29-year-old Tunisian kidney-recipient who was diagnosed simultaneously with post-transplant lymphoproliferative disease (PTLD) and visceral leishmaniasis (VL). Withdrawal of immunosuppressive therapy together with antiparasitic treatment using liposomal amphotericin B, and anti-CD20 antibodies medication resulted in cure of leishmaniasis and remission from PTLD. This case is of clinical interest because of the uncommon association of VL with PTLD after solid organ transplantation. It is also original by the favourable outcome of VL and PTLD, both known as life-threatening diseases. Also, it illustrates the predisposing role of immunosuppressive therapy in occurrence of opportunistic infections and malignancies after solid organ transplantation.
authors.affiliation: Service de médecine interne A, hôpital Charles Nicolle, boulevard du 9-Avril, 1006 BS, Tunis, Tunisie. bachamedmongi@yahoo.fr
authors.forename: Mohamed Mongi
authors.initials: MM
authors.lastname: Bacha
authors.forename: Ezzeddine
authors.initials: E
authors.lastname: Abderrahim
authors.forename: Mondher
authors.initials: M
authors.lastname: Ounissi
authors.forename: Dalel
authors.initials: D
authors.lastname: Chaouech
authors.forename: Mejda
authors.initials: M
authors.lastname: Cherif
authors.forename: Sami
authors.initials: S
authors.lastname: Turki
authors.forename: Hatem
authors.initials: H
authors.lastname: Rajhi
authors.forename: Nadia
authors.initials: N
authors.lastname: Znaidi
authors.forename: Abdessalem
authors.initials: A
authors.lastname: Bahloul
authors.forename: Sonia
authors.initials: S
authors.lastname: Trabelsi
authors.forename: Samira
authors.initials: S
authors.lastname: Khaled
authors.forename: Taïeb
authors.initials: T
authors.lastname: Ben Abdallah
authors.forename: Hedi
authors.initials: H
authors.lastname: Ben Maïz
authors.forename: Adel
authors.initials: A
authors.lastname: Kheder
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000209:etiology* / Q000635:transmission; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000209:etiology*; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000821:virology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011183:Postoperative Complications / Q000209:etiology*; D012074:Remission Induction; D000069283:Rituximab; D020123:Sirolimus / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000981:Antiprotozoal Agents; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D009942:Organometallic Compounds; C068538:liposomal amphotericin B; D000069283:Rituximab; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B; D015774:Ganciclovir; D020123:Sirolimus